Physician profile
Amber H Driskell
NPI 1821158759
$5,023.08
in general payments reported to CMS, 2019-2025
40 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $1,230 · 2021: $1,088 · 2022: $445 · 2023: $429 · 2024: $503 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $759.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $528.90 | 2019-2025 | |
| Amgen INC. | $511.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $508.76 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $430.52 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $365.45 | 2019-2025 | Veozah |
| Abbvie INC. | $328.75 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $163.46 | 2019-2021 | |
| Abbott Laboratories | $132.05 | 2020-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $129.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.23 | 2020-2021 | |
| Allergan, INC. | $86.64 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $82.58 | 2021 | |
| Dexcom, INC. | $80.15 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $70.80 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Driskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.